Immune modulation in cancer with antibodies
DB Page, MA Postow, MK Callahan… - Annual review of …, 2014 - annualreviews.org
Ipilimumab is the prototypical immunomodulatory antibody, approved by the FDA in 2011 for
advanced melanoma on the basis of survival benefit. Since that time, we have made …
advanced melanoma on the basis of survival benefit. Since that time, we have made …
Current landscape of immunotherapy in breast cancer: a review
S Adams, ME Gatti-Mays, K Kalinsky, LA Korde… - JAMA …, 2019 - jamanetwork.com
Importance There is tremendous interest in using immunotherapy to treat breast cancer, as
evidenced by the more than 290 clinical trials ongoing at the time of this narrative review …
evidenced by the more than 290 clinical trials ongoing at the time of this narrative review …
[HTML][HTML] Novel technologies and emerging biomarkers for personalized cancer immunotherapy
The culmination of over a century's work to understand the role of the immune system in
tumor control has led to the recent advances in cancer immunotherapies that have resulted …
tumor control has led to the recent advances in cancer immunotherapies that have resulted …
[HTML][HTML] Video versus direct laryngoscopy for tracheal intubation of critically ill adults
Background Whether video laryngoscopy as compared with direct laryngoscopy increases
the likelihood of successful tracheal intubation on the first attempt among critically ill adults is …
the likelihood of successful tracheal intubation on the first attempt among critically ill adults is …
Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with …
BACKGROUND: Ipilimumab is a monoclonal antibody that antagonizes cytotoxic T
lymphocyte antigen‐4, a negative regulator of the immune system. The authors report on …
lymphocyte antigen‐4, a negative regulator of the immune system. The authors report on …
Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1
J Naidoo, K Schindler, C Querfeld, K Busam… - Cancer immunology …, 2016 - AACR
Monoclonal antibodies (mAb) targeting immune checkpoint pathways such as cytotoxic T-
lymphocyte–associated protein 4 (CTLA-4) and programmed death 1 (PD-1) may confer …
lymphocyte–associated protein 4 (CTLA-4) and programmed death 1 (PD-1) may confer …
A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling
HL McArthur, A Diab, DB Page, J Yuan… - Clinical Cancer …, 2016 - AACR
Purpose: To assess the safety and tolerability of preoperative cryoablation-mediated tumor
antigen presentation and/or ipilimumab-mediated immune modulation in women with …
antigen presentation and/or ipilimumab-mediated immune modulation in women with …
Effect of use of a bougie vs endotracheal tube with stylet on successful intubation on the first attempt among critically ill patients undergoing tracheal intubation: a …
Importance For critically ill adults undergoing emergency tracheal intubation, failure to
intubate the trachea on the first attempt occurs in up to 20% of cases and is associated with …
intubate the trachea on the first attempt occurs in up to 20% of cases and is associated with …
Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
Mounting evidence supports a role for the immune system in breast cancer outcomes. The
ability to distinguish highly immunogenic tumors susceptible to anti-tumor immunity from …
ability to distinguish highly immunogenic tumors susceptible to anti-tumor immunity from …
[HTML][HTML] If we build it they will come: targeting the immune response to breast cancer
Historically, breast cancer tumors have been considered immunologically quiescent, with
the majority of tumors demonstrating low lymphocyte infiltration, low mutational burden, and …
the majority of tumors demonstrating low lymphocyte infiltration, low mutational burden, and …